## TECH: Bio-Techne Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.83 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-5.6% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($57.36)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Bio-Techne Corp. stock outperforms competitors despite losses on the day**
- Source: MarketWatch | 20251205T171700 | Somewhat-Bearish | Relevance: 100%
- Bio-Techne Corp. shares slid 2.93% to $61.68 on Friday, marking its second consecutive day of losses. Despite this decline, the stock still outperformed the broader market, as the S&P 500 Index and Dow Jones Industrial Average both saw gains.

**2. Bio-Techne Corporation (TECH): A Bull Case Theory**
- Source: Finviz | 20251205T170844 | Bullish | Relevance: 100%
- This article summarizes a bullish thesis on Bio-Techne Corporation (TECH), highlighting its evolution into a global leader in life-science consumables and tools. Despite intense competition, Bio-Techne's premium brand and strategic investments support its growth potential in expanding markets. The thesis emphasizes the company's strong financial position, diversified revenue streams, and long-term market expansion opportunities.

**3. 1832 Asset Management L.P. Takes $7.72 Million Position in Bio-Techne Corp $TECH**
- Source: MarketBeat | 20251205T220812 | Somewhat-Bullish | Relevance: 100%
- 1832 Asset Management L.P. has initiated a $7.72 million position in Bio-Techne Corp (NASDAQ:TECH) by purchasing 150,000 shares, representing approximately 0.10% of the company. Other institutional investors have also adjusted their stakes in Bio-Techne, which has a "Moderate Buy" consensus rating from analysts with an average price target of $70.92. The company recently reported earnings in line with estimates and declared a quarterly dividend.

**4. Bio-Techne Corp. stock outperforms competitors despite losses on the day**
- Source: MarketWatch | 20251205T171700 | Somewhat-Bearish | Relevance: 100%
- Bio-Techne Corp. shares fell by 2.93% to $61.68 on Friday, marking its second consecutive day of losses despite an overall positive trading session for the broader market. The S&P 500 Index and the Dow Jones Industrial Average both saw gains.

**5. Bio-Techne Corp. stock outperforms competitors despite losses on the day**
- Source: MarketWatch | 20251205T171700 | Somewhat-Bearish | Relevance: 100%
- Bio-Techne Corp. shares fell by 2.93% to $61.68 on Friday, despite a positive trading session for the broader market. The S&P 500 Index and Dow Jones Industrial Average both saw gains, highlighting Bio-Techne Corp.'s underperformance relative to its competitors. This marks the second consecutive day of losses for the company's stock.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Argus Research | $68 | $65 | +5% |
| 2025-11-06 | UBS | $70 | $65 | +8% |
| 2025-11-06 | Wells Fargo | $70 | $59 | +19% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Argus Research | main | Buy |
| 2025-11-06 | UBS | main | Buy |
| 2025-11-06 | Wells Fargo | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 3 ($0.43M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.5% (-2.7%)
- Blackrock Inc.: 7.6% (-2.3%)
- Morgan Stanley: 4.7% (+10.0%)
- State Street Corpora: 3.7% (-1.8%)
- Wellington Managemen: 3.3% (+349.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +10%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.83 indicates undervaluation relative to growth. Forward P/E 28.4x stretched relative to 10% growth. Balance sheet: strong liquidity (4.2x), low leverage (D/E 0.29). Analyst sentiment positive (3 raises, avg +10%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.2B |
| Beta | 1.46 |
| 52W Range | $46.01 - $79.28 |
| Short Interest | 6.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.83 |
| Forward P/E | 28.4 |
| Current P/E | 31.2 |
| YoY Growth | 10.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 4.1% to -1.5% (-5.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.5pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 50. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.50% (CS: 41) | Neutral |
| RSI_14 | 50.1 | Neutral |
| MACD Histogram | 0.08 | Bullish |
| vs SMA20 | 1.007x | Above |
| vs SMA50 | 1.012x | Above |
| vs SMA200 | 1.112x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $61.68
- **Stop Loss:** $57.36 (7.0% risk)
- **Target:** $70.32 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 115
- **Position Value:** $7,093.20
- **Portfolio %:** 7.09%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-09 (Est: $0.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.42 | $0.42 | -0.4% |
| 2025Q2 | $0.50 | $0.53 | +5.8% |
| 2025Q1 | $0.51 | $0.56 | +10.4% |
| 2024Q4 | $0.39 | $0.42 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*